Journals / Turkish Thoracic Journal / 2020 / Cilt: 21 - Sayı: 6

COVID-19 Treatment at a Glance

Pages
438–445
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Other proposed options include tocilizumab, convalescent plasma, and steroids, but the mainstay of the treatment in intensive care units remains supportive therapies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:As coronavirus disease 2019 (COVID-19) spreads across the world, the ongoing clinical trials are leading to a big race worldwide to develop a treatment that will help control the pandemic.
📊
Key Findings & Data:Unfortunately, COVID-19 does not have any known effective treatment with reliable study results yet.
💡
Conclusion & Impact:Other proposed options include tocilizumab, convalescent plasma, and steroids, but the mainstay of the treatment in intensive care units remains supportive therapies.
🔬Design:Research Article
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Özet

As coronavirus disease 2019 (COVID-19) spreads across the world, the ongoing clinical trials are leading to a big race worldwide to develop a treatment that will help control the pandemic. Unfortunately, COVID-19 does not have any known effective treatment with reliable study results yet. In this pandemic, there is not a lot of time to develop a new specific agent because of the rapid spread of the disease. The process of developing a vaccine is long and requires hard work. Although the pathophysiology of the disease is not fully understood, some of the proposed treatment alternatives are based on old evidence and some have been used with the idea that they might work owing to their mechanism of action. The efficacy, reliability, and safety of the currently available treatment alternatives are therefore a matter of debate. Currently, the main therapies used in the treatment of COVID-19 are antiviral drugs and chloroquine/hydroxychloroquine. Other proposed options include tocilizumab, convalescent plasma, and steroids, but the mainstay of the treatment in intensive care units remains supportive therapies.

🔖

Cite This Article

ARIKAN, H., KARADOĞAN, D., AKYIL, F. T., YÜKSEL, A., TÖREYİN, Z. N., GÜNDÜZ, C., MARİM, F., EYÜBOĞLU, T. Ş., EMİRALİOĞLU, N., GÜRSOY, T. R., ŞERİFOĞLU, İ., SANDAL, A., ÖNCEL, A., ER, B., KÖSE, N., ESENDAĞLI, D., HIZAL, M., ER, A. B., GÜNA, F. E. (2020). COVID-19 Treatment at a Glance. Turkish Thoracic Journal, Cilt: 21 - Sayı: 6, 438–445. https://ajindex.com/articles/417980

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020
  2. 105924. [Crossref] 2. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020:105938. [Crossref] 3. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020
  3. [Crossref] 4. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends 2020
  4. [Crossref] 5. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: Results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020
  5. 105949. [Crossref] 6. Alhazzani W, Moller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med 2020
  6. e440-e469. [Crossref] 7. Bhimraj A, Morgan RL, Shumaker AH, et al. Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America 2020
  7. Available from: https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/ [Crossref] 8. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID-19: An open-label, randomized, controlled trial. medRxiv. 2020:2020.04.10.20060558. [Crossref] 9. Geleris J, Sun Y, Platt J, et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med 2020
  8. [Crossref] 10. Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA 2020
  9. [Crossref] 11. Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: A multinational registry analysis. Lancet (London, England) 2020: DOI:https://doi.org/10.1016/S0140-6736(20)31180-6 [Crossref] 12. Horby P, Mafham M, Linsell L, et al. Effect of Hydroxychloroquine in Hos